Despite reports of positive outcomes from simultaneous agonism of both GLP-1R and Y2-R, this approach alone has not generated the same clinical benefits as obesity surgery64–66. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.